ACT 03
Alternative Names: ACT-03Latest Information Update: 01 Apr 2021
At a glance
- Originator Iproteos
- Developer Accure Therapeutics
- Class Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy
Most Recent Events
- 19 Mar 2021 Preclinical trial in Epilepsy in Spain (IV) prior to March 2021 (Accure Therapeutics pipeline, March 2021)
- 29 May 2020 Iproteos has been acquired and merged into Accure Therapeutics